Alzinova: Interim analyses planned for ADVANCE - Redeye
Bildkälla: Stockfoto

Alzinova: Interim analyses planned for ADVANCE - Redeye

Redeye comments on Alzinova's announcement of the planned interim analyses in its phase IIa study ADVANCE with ALZ-101. The plan comprises a blinded twelve-month interim analysis of biomarkers, clinical measures and safety, together with a separate non-binding futility analysis performed by independent, unblinded statisticians. Both are expected around Q3 2028. We view the plan as sensible, as it introduces a meaningful checkpoint well ahead of the final readout in late 2029.

Redeye comments on Alzinova's announcement of the planned interim analyses in its phase IIa study ADVANCE with ALZ-101. The plan comprises a blinded twelve-month interim analysis of biomarkers, clinical measures and safety, together with a separate non-binding futility analysis performed by independent, unblinded statisticians. Both are expected around Q3 2028. We view the plan as sensible, as it introduces a meaningful checkpoint well ahead of the final readout in late 2029.
Börsvärldens nyhetsbrev